skip to navigation skip to content

Business Weekly: New Multiple Sclerosis treatment wins £1m funding


LIFNanoRx, a venture supported by Cambridge Judge that fights Multiple Sclerosis (MS), will receive £1 million to support its pioneering global solution to treat MS. The funding will support the team as LIFNanoRx moves into clinical development, with the first clinical trial in humans planned to start in 2020-21 at the Blizard Institute. The venture is supported at Cambridge Judge through both the Entrepreneurship Centre’s Accelerate Cambridge programme, and by Cambridge Social Ventures, part of the Centre for Social Innovation.

Read the full article []